- Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials

- 12 of 35 (34%) patients treated per protocol at the recommended Phase 2 dose (RP2D) in combination with FOLFIRI and bevacizumab achieved a complete response or partial response (CR: 1 patient; PR: 11 patients)

- Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli Lilly and Company, and director of Pfizer Oncology Research Unit

- Conference call and webcast to take place on Tuesday, January 18, 2022, at 5:00 PM ET

- Pfizer invests $15 million in Cardiff Oncology common shares

- Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free survival that substantially exceed those seen in historical control trials

- Lead clinical program of onvansertib in KRAS-mutated metastatic colorectal cancer continues to generate data showing robust response to treatment and progression-free survival

- Dr. Ruffner is a US-trained hematologist/oncologist with over 25 years of clinical care, oncology biotechnology and pharmaceutical drug development experience

- Mani Mohindru, Ph.D., Chief Executive Officer of Novasenta, an early-stage biopharmaceutical company, has deep expertise in all phases of drug development, finance, strategy and investor relations

- Trial represents a key component of onvansertib's KRAS-targeted clinical programs and is designed to leverage the synergy of onvansertib when combined with irinotecan/5-FU

- 7 of 18 (39%) evaluable patients in the Phase 1b/2 trial have achieved a partial response to-date

- Evaluable participants (n=20) are heavily pretreated (median of 3 prior lines of treatment); an increase in progression-free survival is a desired outcome